GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (OTCPK:NMLSF) » Definitions » Net Issuance of Preferred Stock

Nova Mentis Life Science (Nova Mentis Life Science) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Nova Mentis Life Science Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Nova Mentis Life Science's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. The number is 0, which means that Nova Mentis Life Science has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Nova Mentis Life Science's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.


Nova Mentis Life Science Net Issuance of Preferred Stock Historical Data

The historical data trend for Nova Mentis Life Science's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Mentis Life Science Net Issuance of Preferred Stock Chart

Nova Mentis Life Science Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nova Mentis Life Science Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Mar24
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nova Mentis Life Science Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nova Mentis Life Science Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Nova Mentis Life Science (Nova Mentis Life Science) Business Description

Traded in Other Exchanges
Address
700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.

Nova Mentis Life Science (Nova Mentis Life Science) Headlines

From GuruFocus

Nova Mentis Begins Enrollment in North American Autism Study

By PRNewswire PRNewswire 03-23-2022

U.S. FDA Approves Nova Mentis Orphan Drug Application

By PRNewswire PRNewswire 11-02-2021

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

By PRNewswire PRNewswire 11-09-2021